Scalper1 News
Biogen (BIIB) on Friday morning is expected to report earnings of $3.91 a share, up 58% vs. a year earlier. That would end a three-quarter string of accelerating growth. Sales should show a 25% advance to $2.66 billion, a solid gain but the fourth straight quarter of decelerating growth. Biogen relies heavily on multiple sclerosis drugs such as Tecfidera and Avonex, which should enjoy another strong quarter. But investors and analysts will be on Scalper1 News
Scalper1 News